$118.02 Million in Sales Expected for TESARO, Inc. (TSRO) This Quarter
Equities analysts expect that TESARO, Inc. (NASDAQ:TSRO) will report sales of $118.02 million for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for TESARO’s earnings. The lowest sales estimate is $33.60 million and the highest is $162.60 million. TESARO posted sales of $3.73 million during the same quarter last year, which suggests a positive year over year growth rate of 3,064.1%. The company is scheduled to report its next earnings report on Thursday, November 2nd.
On average, analysts expect that TESARO will report full-year sales of $118.02 million for the current year, with estimates ranging from $108.10 million to $280.80 million. For the next year, analysts anticipate that the business will report sales of $484.25 million per share, with estimates ranging from $312.94 million to $636.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover TESARO.
TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the consensus estimate of ($2.52) by ($0.30). TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The firm had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. During the same period in the prior year, the business posted ($1.28) earnings per share. TESARO’s quarterly revenue was down 17.6% compared to the same quarter last year.
A number of research firms have recently issued reports on TSRO. Oppenheimer Holdings, Inc. began coverage on shares of TESARO in a report on Thursday, May 25th. They issued an “outperform” rating and a $183.00 price objective on the stock. Cann reiterated an “outperform” rating on shares of TESARO in a report on Wednesday, May 24th. Credit Suisse Group set a $198.00 price objective on shares of TESARO and gave the company a “buy” rating in a report on Monday, June 5th. Wedbush upgraded shares of TESARO to an “outperform” rating and set a $168.00 price objective on the stock in a report on Monday, June 5th. Finally, FBR & Co lowered their price objective on shares of TESARO from $200.00 to $195.00 and set a “mkt perform” rating on the stock in a report on Monday, June 5th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. TESARO presently has a consensus rating of “Buy” and an average price target of $171.42.
In other TESARO news, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction on Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Edward C. English sold 10,862 shares of TESARO stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the transaction, the vice president now directly owns 6,258 shares of the company’s stock, valued at $844,329.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,100 shares of company stock valued at $3,387,465. Company insiders own 40.50% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in TSRO. BlackRock Inc. boosted its position in TESARO by 4,504.8% during the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock worth $524,643,000 after purchasing an additional 3,335,611 shares during the period. Janus Henderson Group PLC bought a new position in TESARO during the second quarter worth $100,301,000. PointState Capital LP bought a new position in TESARO during the second quarter worth $85,971,000. TIAA CREF Investment Management LLC boosted its position in TESARO by 167.9% during the first quarter. TIAA CREF Investment Management LLC now owns 367,519 shares of the biopharmaceutical company’s stock worth $56,550,000 after purchasing an additional 230,353 shares during the period. Finally, Pioneer Investment Management Inc. boosted its position in TESARO by 195.6% during the second quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock worth $44,441,000 after purchasing an additional 210,273 shares during the period.
TESARO (TSRO) traded up 0.08% during trading on Friday, reaching $115.33. 191,162 shares of the company’s stock were exchanged. TESARO has a 12 month low of $96.52 and a 12 month high of $192.94. The firm’s market cap is $6.25 billion. The firm’s 50-day moving average price is $122.01 and its 200-day moving average price is $140.92.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.